15 Jan 2026
// PRESS RELEASE
11 Dec 2025
// PRESS RELEE
01 Nov 2025
// PRESS RELEASE
KEY PRODUCTS
KEY SERVICESYour reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market
About
BIO-Europe SpringBIO-Europe Spring
Industry Trade Show
Attending
23-25 March, 2026
Pharma Contract Manufa...Pharma Contract Manufacturing
Industry Trade Show
Attending
23-25 March, 2026
Industry Trade Show
Attending
23-26 March, 2026
CONTACT DETAILS





Events
Webinars & Exhibitions
BIO-Europe SpringBIO-Europe Spring
Industry Trade Show
Attending
23-25 March, 2026
Pharma Contract Manufa...Pharma Contract Manufacturing
Industry Trade Show
Attending
23-25 March, 2026
Industry Trade Show
Attending
23-26 March, 2026
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

15 Jan 2026
// PRESS RELEASE
https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-recognized-as-a-top-employer/

11 Dec 2025
// PRESS RELEE
https://www.agcpharmachemicals.com/en/news/the-key-role-of-project-management-in-a-cdmo/

01 Nov 2025
// PRESS RELEASE
https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-receives-a-platinum-medal-from-ecovadis/

25 Oct 2025
// PRESS RELEASE
https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-inaugurates-a-new-advanced-manufacturing-plant-in-malgrat-de-mar-barcelona-with-an-investment-of-over-100-million-euros/

22 Oct 2025
// PRESS RELEASE
https://www.agcpharmachemicals.com/en/news/setting-new-standards-in-micronization-with-hosokawa-technology/

26 Sep 2025
// PRESS RELEASE
https://www.agcpharmachemicals.com/en/news/agc-pharma-chemicals-to-attend-the-54th-organic-process-research-development-conference-in-lisbon/
NDC Package Code : 65404-008
Start Marketing Date : 2024-06-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR ...
NDC Package Code : 65404-005
Start Marketing Date : 1999-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR ...
NDC Package Code : 65404-004
Start Marketing Date : 2016-02-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
VMF Number : 5897
Submission : 2007-06-15
Status : Active
Type : II
NDC Package Code : 65404-006
Start Marketing Date : 2004-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
Registrant Name : IMCD Korea Co., Ltd.
Registration Date : 2021-09-28
Registration Number : 20210325-209-J-909(1)
Manufacturer Name : AGC Pharma Chemicals Europe SLU
Manufacturer Address : Cami de la Pomereda, 13, 08380 Malgrat de Mar, Barcelona, Spain
NDC Package Code : 65404-007
Start Marketing Date : 2004-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR ...
Registrant Name : Boehringer Ingelheim Korea Co., Ltd.
Registration Date : 2021-03-25
Registration Number : 20210325-209-J-909
Manufacturer Name : AGC Pharma Chemicals Europe SLU
Manufacturer Address : Camí de la Pomereda, 13, 08380 Malgrat de Mar, Barcelona, Spain
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 65404-008
Start Marketing Date : 2024-06-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR HUMAN PR...
NDC Package Code : 65404-005
Start Marketing Date : 1999-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR HUMAN PR...
NDC Package Code : 65404-004
Start Marketing Date : 2016-02-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65404-007
Start Marketing Date : 2004-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT FOR HUMAN PR...
NDC Package Code : 65404-006
Start Marketing Date : 2004-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
About the Company : AGC Pharma Chemicals Europe is a leading CDMO partner for Small Molecule APIs, HPAPIs, and intermediates. It provides comprehensive, agile, and innovative solutions throughout the entire lifecyc...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
The collaboration aims for the development of an API for the treatment of pancreatic cancer, ABTL0812 (ibrilatazar), currently in clinical trials.
Lead Product(s): Ibrilatazar
Therapeutic Area: Oncology Brand Name: ABTL0812
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Ability Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 16, 2024
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Ability Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
AGC Pharma and AbilityPharma to Produce Innovative Treatment for Pancreatic Cancer
Details : The collaboration aims for the development of an API for the treatment of pancreatic cancer, ABTL0812 (ibrilatazar), currently in clinical trials.
Product Name : ABTL0812
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 16, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Services
Analytical
API Manufacturing
Pharma Service : API Manufacturing
Category : Fine Chemical / Intermediate
Sub Category : Overview
Pharma Service : API Manufacturing
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API & Drug Product Development
ABOUT THIS PAGE
AGC Pharma Chemicals Europe is a supplier offers 7 products (APIs, Excipients or Intermediates).
Find a price of Dapiprazole Hydrochloride bulk offered by AGC Pharma Chemicals Europe
Find a price of Dipyridamole bulk offered by AGC Pharma Chemicals Europe
Find a price of Gliquidone bulk offered by AGC Pharma Chemicals Europe
Find a price of Mexiletine bulk offered by AGC Pharma Chemicals Europe
Find a price of Pimobendan bulk offered by AGC Pharma Chemicals Europe
Find a price of Pirenzepine bulk offered by AGC Pharma Chemicals Europe
Find a price of Telmisartan bulk offered by AGC Pharma Chemicals Europe
AGC Pharma Chemicals Europe



